75
Participants
Start Date
August 10, 2020
Primary Completion Date
March 31, 2022
Study Completion Date
April 28, 2022
PF-06865571
Tablet
PF-05221304
Tablet
Placebo
Tablet
National Clinical Research, Inc., Richmond
Floridian Clinical Research, LLC, Miami Lakes
Optimus U Corporation, Miami
Excel Medical Clinical Trials, Boca Raton
L-MARC Research Center, Louisville
The Christ Hospital, Cincinnati
Sterling Research Group, Ltd., Cincinnati
Clinical Trials of Texas, Inc., San Antonio
Catalina Research Institute, LLC, Montclair
Clinical Trials Research, Lincoln
East-West Medical Research Institute, Honolulu
Nova Scotia Health Authority QE II Health Sciences Centre, Halifax
Nova Scotia Health Authority QE II Health Sciences Centre, Halifax
Nova Scotia Health Authority - Queen Elizabeth II Health Sciences Centre, Halifax
Aggarwal and Associates Limited, Brampton
Milestone Research Inc., London
Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi
Ecogene-21, Chicoutimi
Alpha Recherche Clinique, Québec
Centre de Recherche Saint-Louis, Québec
Lead Sponsor
Pfizer
INDUSTRY